Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
PurposeIt is well-known that the pathological complete response (pCR) rate in patients with luminal A cancer (LAC) is lower than those of other subtypes of breast cancer. The phenotype of cancer often alters after neoadjuvant chemotherapy (NAC) which may be related to hypoxia, and the latter might i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.630065/full |
| _version_ | 1818242377954885632 |
|---|---|
| author | Yushi Liu Ye Kang Jianyi Li Yang Zhang Shi Jia Qiang Sun Yan Ma Jing Zhang Zhenrong Wang Yanan Cao Yang Shen |
| author_facet | Yushi Liu Ye Kang Jianyi Li Yang Zhang Shi Jia Qiang Sun Yan Ma Jing Zhang Zhenrong Wang Yanan Cao Yang Shen |
| author_sort | Yushi Liu |
| collection | DOAJ |
| description | PurposeIt is well-known that the pathological complete response (pCR) rate in patients with luminal A cancer (LAC) is lower than those of other subtypes of breast cancer. The phenotype of cancer often alters after neoadjuvant chemotherapy (NAC) which may be related to hypoxia, and the latter might induce the drift of the estrogen receptor (ER). The phenotype drift in local advanced LAC after NAC might influence the long-term prognosis.MethodsThe oxygen concentration of cancer tissues during NAC was recorded and analyzed (n = 43). The expression of ER and claudin-6 was detected in pre- and post-NAC specimens.ResultsNAC might induce the cycling intracanceral hypoxia, and the pattern was related to NAC response. The median follow-up time was 61 months. Most of the patients (67%) with stable or increased ER and claudin-6 expression exhibited perfect prognosis (DFS = 100%, 61 months). About 20% of patients with decreased claudin-6 would undergo the poor prognosis (DFS = 22.2%, 61 months). The contrasting prognosis (100% vs. 22.2%) had nothing to do with the response of NAC in the above patients. Only 13% patients had stable claudin-6 and decreased ER, whose prognosis might relate to the response of NAC.ConclusionNAC might induce cycling intracanceral hypoxia to promote the phenotype drift in local advanced LAC, and the changes in ER and claudin-6 after NAC would determine the long-term prognosis. |
| first_indexed | 2024-12-12T13:44:16Z |
| format | Article |
| id | doaj.art-318bf98f8b3b4df88c5ec8fc7b709b3a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T13:44:16Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-318bf98f8b3b4df88c5ec8fc7b709b3a2022-12-22T00:22:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.630065630065Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant ChemotherapyYushi Liu0Ye Kang1Jianyi Li2Yang Zhang3Shi Jia4Qiang Sun5Yan Ma6Jing Zhang7Zhenrong Wang8Yanan Cao9Yang Shen10Department of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, Liaoning Cancer Hospital, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, Benxi Iron and Steel Co. General Hospital, Benxi, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaDepartment of Breast Surgery, ShengJing Hospital of China Medical University, Shenyang, ChinaPurposeIt is well-known that the pathological complete response (pCR) rate in patients with luminal A cancer (LAC) is lower than those of other subtypes of breast cancer. The phenotype of cancer often alters after neoadjuvant chemotherapy (NAC) which may be related to hypoxia, and the latter might induce the drift of the estrogen receptor (ER). The phenotype drift in local advanced LAC after NAC might influence the long-term prognosis.MethodsThe oxygen concentration of cancer tissues during NAC was recorded and analyzed (n = 43). The expression of ER and claudin-6 was detected in pre- and post-NAC specimens.ResultsNAC might induce the cycling intracanceral hypoxia, and the pattern was related to NAC response. The median follow-up time was 61 months. Most of the patients (67%) with stable or increased ER and claudin-6 expression exhibited perfect prognosis (DFS = 100%, 61 months). About 20% of patients with decreased claudin-6 would undergo the poor prognosis (DFS = 22.2%, 61 months). The contrasting prognosis (100% vs. 22.2%) had nothing to do with the response of NAC in the above patients. Only 13% patients had stable claudin-6 and decreased ER, whose prognosis might relate to the response of NAC.ConclusionNAC might induce cycling intracanceral hypoxia to promote the phenotype drift in local advanced LAC, and the changes in ER and claudin-6 after NAC would determine the long-term prognosis.https://www.frontiersin.org/articles/10.3389/fonc.2022.630065/fullluminal A breast cancercycling hypoxiaestrogen receptorclaudin-6neoadjuvant chemotherapy |
| spellingShingle | Yushi Liu Ye Kang Jianyi Li Yang Zhang Shi Jia Qiang Sun Yan Ma Jing Zhang Zhenrong Wang Yanan Cao Yang Shen Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy Frontiers in Oncology luminal A breast cancer cycling hypoxia estrogen receptor claudin-6 neoadjuvant chemotherapy |
| title | Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy |
| title_full | Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy |
| title_fullStr | Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy |
| title_full_unstemmed | Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy |
| title_short | Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy |
| title_sort | estrogen receptor and claudin 6 might play vital roles for long term prognosis in patients with luminal a breast cancer who underwent neoadjuvant chemotherapy |
| topic | luminal A breast cancer cycling hypoxia estrogen receptor claudin-6 neoadjuvant chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.630065/full |
| work_keys_str_mv | AT yushiliu estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT yekang estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT jianyili estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT yangzhang estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT shijia estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT qiangsun estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT yanma estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT jingzhang estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT zhenrongwang estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT yanancao estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy AT yangshen estrogenreceptorandclaudin6mightplayvitalrolesforlongtermprognosisinpatientswithluminalabreastcancerwhounderwentneoadjuvantchemotherapy |